$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
厄洛替尼治疗基因突变的NSCLC患者
2025-10-19 11:44:20
Check Details
吉非替尼获批NSCLC患者一线治疗用药
2025-10-19 11:44:20
Check Details
吉非替尼治疗晚期非小细胞肺癌前瞻性II期试验
2025-10-19 11:44:20
Check Details
易瑞沙对肺癌治疗的效果很好
2025-10-19 11:44:20
Check Details
厄洛替尼不能与CYP3A4 抑制剂同时服用
2025-10-19 11:44:20
Check Details
易瑞沙治疗肺癌效果因人而异
2025-10-19 11:44:20
Check Details
厄洛替尼单药治疗晚期NSCLC的效果
2025-10-19 11:44:20
Check Details
阿来替尼可延长ALK阳性NSCLC患者生存时间
2025-10-19 11:44:20
Check Details
艾乐替尼治疗肺癌脑转移疗效显著
2025-10-19 11:44:20
Check Details
奥希替尼的耐药机制与耐药原因
2025-10-19 11:44:20
Check Details
克唑替尼ROS1阳性的晚期非小细胞肺癌靶向药
2025-10-19 11:44:20
Check Details
色瑞替尼第二代ALK抑制剂
2025-10-19 11:44:20
Check Details
1
2
...
2993
2994
2995
2996
2997
2998
2999
...
4160
4161
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Mirdametinib Mechanism and Clinical Guide: MEK Inhibitor for NF1 Plexiform Neurofibromas
2
Acalabrutinib Dosing and Efficacy Guide: Administration, Response Evaluation, and Safety
3
Osimertinib Treatment and Dosing Guide: Efficacy, Administration, and Precautions
4
Ceritinib Dosing Guide: 450mg Once Daily with Food – Key Administration Points
5
Ruxolitinib Drug Safety Guide: Drug Interactions, Hepatic/Renal Function, and Infection Risk Management
6
Belzutifan (WELIREG) Treatment Guide: Duration, Onset of Action, and Monitoring Protocol
7
Lapatinib Side Effects: Managing Diarrhea, Skin Reactions, and Liver Function Changes
8
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
9
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
10
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
11
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
12
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide